Montelukast Ametas

Montelukast, the active ingredient in Montelukast Ametas, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is prescribed to manage asthma and allergic rhinitis in adults and children by reducing airway inflammation and nasal symptoms, improving breathing and quality of life.

GNH USA supplies Montelukast Ametas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets, including compliance with WHO GMP guidelines.

Montelukast is a leukotriene receptor antagonist used to treat conditions mediated by leukotriene‑driven inflammation. - Asthma: reduces frequency of wheezing episodes and improves lung function. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate head pain. - Abdominal pain: discomfort in the stomach area. - Cough: occasional dry cough. - Nausea: feeling of queasiness.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Mood changes: depression, anxiety, or suicidal thoughts. - Hepatic enzyme elevation: increased liver function test results.

Before initiating therapy, consider the following safety measures. - Pregnancy: consult a healthcare provider as safety data are limited. - Breastfeeding: discuss potential risks with a physician. - Liver impairment: use with caution and monitor hepatic function. - Concomitant use with phenobarbital or rifampin: may reduce effectiveness. - Age considerations: not established for children under 12 months. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Montelukast can interact with other medicines; monitor as indicated.

Major Interactions (Avoid): - Phenobarbital: may decrease plasma levels of montelukast. - Rifampin: may reduce therapeutic efficacy. - Strong CYP3A4 inhibitors: may increase systemic exposure.

Moderate Interactions (Monitor Closely): - Warfarin: possible increased anticoagulant effect. - Beta‑agonists: additive bronchodilation may occur.